Business

Articles

Bright Path will develop and produce APIs for hospitals facing drug shortages in the Capstone Health Alliance.

Capstone Health Alliance and Bright Path Laboratories Enter Drug Shortage Agreement

The formulation will be used to mitigate emerging infectious diseases and public health emergencies.

Revive Therapeutics Announces Initiation of New Bucillamine Formulation Development

The deal is worth up to $36 million with an initial upfront consideration of $14 million, with an additional $22 million in contingent value rights (CVRs) that is payable upon achieving certain milestones.

LEO Pharma to Acquire Timber Pharmaceuticals

A major grant from the Bill & Melinda Gates Foundation will bolster efforts to fight the global HIV/AIDS epidemic.

Absci and Caltech Collaborate to Accelerate Affordable HIV Therapeutic Vaccine

The collaboration between Parexel and Partex is designed to leverage artificial intelligence-powered solutions to accelerate drug discovery and development.

Parexel and Partex Enter AI Alliance

Gilead and Tentarix established three multi-year collaborations to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. 

Gilead and Tentarix Strike Three Cancer And Inflammation Partnership Deals

Zygel is the first and only pharmaceutically manufactured, synthetic cannabidiol that is formulated as a patient-protected permeation-enhanced gel for transdermal delivery.

Harmony Biosciences to Acquire Zynerba Pharmaceuticals

Feliza Mirasol is the science editor for 

The completion of three acquisitions of Versanis Bio, Sigilon Therapeutics, and DICE Therapeutics boosts Eli Lilly and Company’s product pipeline in obesity, diabetes, and immunology.

Lilly Completes Spate of Acquisitions

Under the exclusive agreement, Hikma will commercialize products in Rakuten Medical’s pipeline for cancer treatment in the Middle East and North Africa region.

Rakuten Medical Signs Exclusive Licensing Agreement with Hikma for Cancer Treatments in MENA

A report from the UK Bioindustry Association report indicated that biotech venture and public financing rose from £295 million in the first quarter to £382 million in the second quarter.

Business News